Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 353

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 353
---
310,739 $136.42 Granted5,558 168.62 Granted in acquisitions605 168.24 Vested(6,052)128.28 Forfeited(463)152.79 Outstanding at December 31, 202410,387 $159.52 The fair market value of RSUs and performance shares (as applicable) vested was $1.1 billion in 2024, $1.0 billion in 2023 and $1.0 billion in 2022.In connection with the ImmunoGen and Cerevel Therapeutics acquisitions, AbbVie issued 0.6 million RSUs to holders of ImmunoGen and Cerevel Therapeutics equity awards based on a conversion factor described in each of the transaction agreements. See Note 5 for additional information regarding the ImmunoGen and Cerevel Therapeutics acquisitions.As of December 31, 2024, $655 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.Cash DividendsCash dividends declared per common share totaled $6.29 in 2024, $5.99 in 2023 and $5.71 in 2022. The following table summarizes quarterly cash dividends declared during 2024, 2023 and 2022:202420232022Date DeclaredPayment DateDividend Per ShareDate DeclaredPayment DateDividend Per ShareDate DeclaredPayment DateDividend Per Share10/30/2402/14/25$1.6410/26/2302/15/24$1.5510/28/2202/15/23$1.4809/06/2411/15/24$1.5509/08/2311/15/23$1.4809/09/2211/15/22$1.4106/21/2408/15/24$1.5506/22/2308/15/23$1.4806/23/2208/15/22$1.4102/15/2405/15/24$1.5502/16/2305/15/23$1.4802/17/2205/16/22$1.41Stock Repurchase ProgramThe company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or